跳至主要内容
临床试验/NCT04304924
NCT04304924Unknown不适用

Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer

Gustave Roussy, Cancer Campus, Grand Paris2 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2020年6月17日最近更新:
适应症

试验速览

阶段
不适用
入组人数
220
试验地点
2
主要终点
Fatigue

研究概览

简要总结

The primary objective of MEDEA is to compare the effect of a personalised telephone-based health education weight loss program based on motivational coaching, exercise and diet versus a standard health educational program control on fatigue of overweight or obese BC patients (as measured by the EORTC QLQ C30 (Aaronson et al. 1993; Sprangers et al. 1996))

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • This study will be focused on an overweight/obese (BMI ≥25 kg/m2) population of patients with early BC. Particularly, patients will be eligible if they have:
  • Documentation of Disease:
  • Subjects must have histologically confirmed invasive BC and registration must occur within 12 months after the end of active treatment,
  • Bilateral breast carcinoma is allowed,
  • Patients must have Stage I toIII BC and no evidence of distant metastatic or locally recurrent disease,
  • No history of invasive BC in 5 years prior to study registration other than the current diagnosis (prior Ductal Carcinoma in situ (DCIS) at any time does not make a patient ineligible).
  • Documentation of overweight/obesity: Subjects must have a BMI ≥25 kg/m2 objectively assessed at the time of eligibility evaluation or reported in the medical records within 56 days prior to study registration. The most recent BMI obtained must be used for eligibility. If most recent BMI is <25 then the patient is not eligible to enroll.
  • Prior Treatment :
  • All adjuvant or neoadjuvant CT, radiation, and surgery completed at least 21 days prior to registration to a maximum of 365 days after the end of treatment,
  • Patients may have breast reconstruction during protocol participation, but definitive BC surgery must be completed at least 21 days prior to registration,
  • Biologic therapy, hormonal therapy, and bisphosphonates are acceptable.
  • Age ≥ 18 years,
  • ECOG Performance Status 0 or 1,
  • Self-reported ability to walk at least 400 metres (at any pace),
  • Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol,
  • Patients must be affiliated to a social security system or beneficiary of the same.

排除标准

  • Participation in another clinical study with an investigational product that has Fatigue as a known frequent adverse effects during the last 3 months and while on study treatment,
  • Participating in another weight loss, physical activity or dietary intervention clinical trial. Participants in both arms are also allowed to pursue weight loss and physical activity programs on their own, as long as these programs are not provided as part of a clinical trial,
  • Comorbid conditions, such as other malignancy, diabetes, inflammatory bowel disease, history of severe cardiovascular, respiratory or musculoskeletal disease that would preclude adherence to the study diet or physical activity program or significantly affect the physical status, or the ability to give an informed consent,
  • Secondary overweight or obesity documented or suspected,
  • Chronic consumption of corticosteroids,
  • Self reported pregnancy or intent to become pregnant in the year after enrollement,
  • Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

结局指标

主要结局

Fatigue

时间窗: up to 12 months

will be assessed using the EORTC QLQ-C30 questionnaire

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验